98 research outputs found
Quantifying cancer patient survival : extensions and applications of cure models and life expectancy estimation
Cancer patient survival is the single most important measure of cancer patient care. By
quantifying cancer patient survival in different ways further insights can be gained in terms of
temporal trends and differences in cancer patient survival between groups. The objective of this
thesis is to develop and apply methods for estimating the cure proportion and loss in expectation of
life for cancer patients.
In paper I, a cure model was used to study temporal trends in survival of patients with
acute myeloid leukaemia in Sweden. Cancer patient survival was estimated in a relative survival
setting and quantified as the proportion cured and the median survival time of uncured for different
age groups and by calendar time of diagnosis. We found a dramatic increase in the cure proportion
for the age group 19-40, although almost no improvement was seen for patients aged 70-79 at
diagnosis.
In paper II, a flexible parametric cure model was developed to overcome some
limitations with standard parametric cure models. This model is a special case of a non-mixture
cure model, using splines instead of a parametric distribution for the modeling. The fit of the
flexible parametric cure model was compared to the fit of a Weibull non-mixture cure model, and
shown to be superior in cases when the standard non-mixture cure model did not give a good fit or
did not converge. Software was developed to enable use of the method.
In paper III, the possibility of using a flexible parametric relative survival model for
estimating life expectancy and loss in expectation of life was evaluated. Extrapolation of the
survival function is generally needed, and the flexible parametric relative survival model was
shown to extrapolate the survival very well. The method was evaluated by comparing survival
functions extrapolated from 10 years past diagnosis to observed survival by the use of data with 40
years of follow-up. Software was developed to enable use of the method.
In paper IV, the life expectancy and loss in expectation of life was estimated for colon
cancer patients in Sweden. Even though relative survival was similar across age for colon cancer
patients, the loss in expectation of life varied greatly by age, since young patients have more years
to lose. We also found that the life expectancy of colon cancer patients improved over time.
However, the improvement has to a large extent mimicked the improvement seen in the general
population, and therefore there were no large changes in the loss in expectation of life.
In conclusion, the methods presented in this thesis are additional tools for estimating
and quantifying population-based cancer patient survival, that can lead to an improved
understanding of different aspects of the prognosis of cancer patients
A multi-state model incorporating estimation of excess hazards and multiple time scales
As cancer patient survival improves, late effects from treatment are becoming
the next clinical challenge. Chemotherapy and radiotherapy, for example,
potentially increase the risk of both morbidity and mortality from second
malignancies and cardiovascular disease. To provide clinically relevant
population-level measures of late effects, it is of importance to (1)
simultaneously estimate the risks of both morbidity and mortality, (2)
partition these risks into the component expected in the absence of cancer and
the component due to the cancer and its treatment, and (3) incorporate the
multiple time scales of attained age, calendar time, and time since diagnosis.
Multi-state models provide a framework for simultaneously studying morbidity
and mortality, but do not solve the problem of partitioning the risks. However,
this partitioning can be achieved by applying a relative survival framework, by
allowing is to directly quantify the excess risk. This paper proposes a
combination of these two frameworks, providing one approach to address (1)-(3).
Using recently developed methods in multi-state modeling, we incorporate
estimation of excess hazards into a multi-state model. Both intermediate and
absorbing state risks can be partitioned and different transitions are allowed
to have different and/or multiple time scales. We illustrate our approach using
data on Hodgkin lymphoma patients and excess risk of diseases of the
circulatory system, and provide user-friendly Stata software with accompanying
example code
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life expectancy, whereas patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately reduced survival in most, but not all, studies. We conducted a large population-based study to establish patterns of survival in more than 9,000 patients with MPNs. We identified 9,384 patients with MPNs (from the Swedish Cancer Register) diagnosed from 1973 to 2008 (divided into four calendar periods) with follow-up to 2009. Relative survival ratios (RSRs) and excess mortality rate ratios were computed as measures of survival. Patient survival was considerably lower in all MPN subtypes compared with expected survival in the general population, reflected in 10-year RSRs of 0.64 (95% CI, 0.62 to 0.67) in patients with PV, 0.68 (95% CI, 0.64 to 0.71) in those with ET, and 0.21 (95% CI, 0.18 to 0.25) in those with PMF. Excess mortality was observed in patients with any MPN subtype during all four calendar periods (P < .001). Survival improved significantly over time (P < .001); however, the improvement was less pronounced after the year 2000 and was confined to patients with PV and ET. We found patients with any MPN subtype to have significantly reduced life expectancy compared with the general population. The improvement over time is most likely explained by better overall clinical management of patients with MPN. The decreased life expectancy even in the most recent calendar period emphasizes the need for new treatment options for these patients.Swedish Cancer Society
CAN 2009/1203
Stockholm County Council
SLL 20090201
Karolinska Institutet
SLL 20090201
Karolinska Institutet Foundations
2009Fobi0072
Shire Pharmaceuticals
Adolf H. Lundin Charitable Foundatio
The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study.
AbstractObjectiveThe Nordic Nutrition Recommendations (NNR) aim at preventing diet-associated diseases such as cancer in the Nordic countries. We evaluated adherence to the NNR in relation to prostate cancer (PC) in Swedish men, including potential interaction with a genetic risk score and with lifestyle factors.DesignPopulation-based case–control study (Cancer of the Prostate in Sweden (CAPS), 2001–2002). Using data from a semi-quantitative FFQ, we created an NNR adherence score and estimated relative risks of PC by unconditional logistic regression. Individual score components were modelled separately and potential modifying effects were assessed on the multiplicative scale.SettingFour regions in the central and northern parts of Sweden.SubjectsIncident PC patients (n 1386) and population controls (n 940), frequency-matched on age and region.ResultsNo overall association with PC was found, possibly due to the generally high adherence to the NNR score and its narrow distribution in the study population. Among individual NNR score components, high compared with low intakes of polyunsaturated fat were associated with an increased relative risk of localized PC. No formal interaction with genetic or lifestyle factors was observed, although in stratified analysis a positive association between the NNR and PC was suggested among men with a high genetic risk score but not among men with a medium or low genetic risk score.ConclusionsOur findings do not support an association between NNR adherence and PC. The suggestive interaction with the genetic risk score deserves further investigations in other study populations
Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study
Background
Except for overall survival, whether or not waiting time for treatment could influences other domains of cancer patients’ overall well-being is to a large extent unknown. Therefore, we performed this study to determine the effect of waiting time for cancer treatment on the mental health of patients with esophageal or gastric cancer.
Methods
Based on the Swedish National Quality Register for Esophageal and Gastric Cancers (NREV), we followed 7,080 patients diagnosed 2006–2012 from the time of treatment decision. Waiting time for treatment was defined as the interval between diagnosis and treatment decision, and was classified into quartiles. Mental disorders were identified by either clinical diagnosis through hospital visit or prescription of psychiatric medications. For patients without any mental disorder before treatment, the association between waiting time and subsequent onset of mental disorders was assessed by hazard ratios (HRs) with 95% confidence interval (CI), derived from multivariable-adjusted Cox model. For patients with a preexisting mental disorder, we compared the rate of psychiatric care by different waiting times, allowing for repeated events.
Results
Among 4,120 patients without any preexisting mental disorder, lower risk of new onset mental disorders was noted for patients with longer waiting times, i.e. 18–29 days (HR 0.86; 95% CI 0.74-1.00) and 30–60 days (HR 0.79; 95% CI 0.67-0.93) as compared with 9–17 days. Among 2,312 patients with preexisting mental disorders, longer waiting time was associated with more frequent psychiatric hospital care during the first year after treatment (37.5% higher rate per quartile increase in waiting time; p for trend = 0.0002). However, no such association was observed beyond one year nor for the prescription of psychiatric medications.
Conclusions
These data suggest that waiting time to treatment for esophageal or gastric cancer may have different mental health consequences for patients depending on their past psychiatric vulnerabilities. Our study sheds further light on the complexity of waiting time management, and calls for a comprehensive strategy that takes into account different domains of patient well-being in addition to the overall survival.This study was partly supported by the Swedish Cancer Society (grant No: CAN 2014/417).Peer Reviewe
Recommended from our members
Aspirin intake and breast cancer survival – a nation-wide study using prospectively recorded data in Sweden
Background: Aspirin (ASA) use has been associated with improved breast cancer survival in several prospective studies. Methods: We conducted a nested case–control study of ASA use after a breast cancer diagnosis among women using Swedish National Registries. We assessed prospectively recorded ASA exposure during several different time windows following cancer diagnosis using conditional logistic regression with breast cancer death as the main outcome. Within each six-month period of follow-up, we categorized dispensed ASA doses into three groups: 0, less than 1, and 1 or more daily doses. Results: We included 27,426 women diagnosed with breast cancer between 2005 and 2009; 1,661 died of breast cancer when followed until Dec 31, 2010. There was no association between ASA use and breast cancer death when exposure was assessed either shortly after diagnosis, or 3–12 months before the end of follow-up. Only during the period 0–6 months before the end of follow-up was ASA use at least daily compared with non-use associated with a decreased risk of breast cancer death: HR (95% CI) = 0.69 (0.56-0.86). However, in the same time-frame, those using ASA less than daily had an increased risk of breast cancer death: HR (95% CI) = 1.43 (1.09-1.87). Conclusions: Contrary to other studies, we did not find that ASA use was associated with a lower risk of death from breast cancer, except when assessed short term with no delay to death/end of follow-up, which may reflect discontinuation of ASA during terminal illness
Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer
Background: Physical activity has been shown to reduce the risk of colon, endometrial and postmenopausal breast cancer. The aim of this study was to quantify the proportion of the cancer burden in the Nordic countries linked to insufficient levels of leisure time physical activity and estimate the potential for cancer prevention for these three sites by increasing physical activity levels. Methods: Using the Prevent macrosimulation model, the number of cancer cases in the Nordic countries over a 30-year period (2016-2045) was modelled, under different scenarios of increasing physical activity levels in the population, and compared with the projected number of cases if constant physical activity prevailed. Physical activity (moderate and vigorous) was categorised according to metabolic equivalents (MET) hours in groups with sufficient physical activity (15+ MET-hours/week), low deficit (9 to Results: If no one had insufficient levels of physical activity, about 11,000 colon, endometrial and postmenopausal breast cancer cases could be avoided in the Nordic countries in a 30-year period, which is 1% of the expected cases for the three cancer types. With a 50% reduction in all deficit groups by 2025 or a 100% reduction in the group of high deficit, approximately 0.5% of the expected cases for the three cancer types could be avoided. The number and percentage of avoidable cases was highest for colon cancer. Conclusion: 11,000 cancer cases could be avoided in the Nordic countries in a 30-year period, if deficit in physical activity was eliminated. (C) 2019 Elsevier Ltd. All rights reserved.Peer reviewe
Recommended from our members
Mediterranean Diet Score and prostate cancer risk in a Swedish population-based case–control study
Several individual components of the Mediterranean diet have been shown to offer protection against prostate cancer. The present study is the first to investigate the association between adherence to the Mediterranean diet and the relative risk of prostate cancer. We also explored the usefulness of the Mediterranean Diet Score (MDS) in a non-Mediterranean population. FFQ data were obtained from 1482 incident prostate cancer patients and 1108 population-based controls in the Cancer of the Prostate in Sweden (CAPS) study. We defined five MDS variants with different components or using either study-specific intakes or intakes in a Greek reference population as cut-off values between low and high intake of each component. Unconditional logistic regression was used to estimate the relative risk of prostate cancer for high and medium v. low MDS, as well as potential associations with the individual score components. No statistically significant association was found between adherence to the Mediterranean diet based on any of the MDS variants and prostate cancer risk (OR range: 0·96–1·19 for total prostate cancer, comparing high with low adherence). Overall, we found little support for an association between the Mediterranean diet and prostate cancer in this Northern European study population. Despite potential limitations inherent in the study or in the build-up of a dietary score, we suggest that the original MDS with study-specific median intakes as cut-off values between low and high intake is useful in assessing the adherence to the Mediterranean diet in non-Mediterranean populations
Screening and cervical cancer cure: population based cohort study
Objective To determine whether detection of invasive cervical cancer by screening results in better prognosis or merely increases the lead time until death
- …